News

Filter

Current filters:

Zavesca

1 to 9 of 42 results

Actelion’s PAH drugs boost 4% rise in sales

Actelion’s PAH drugs boost 4% rise in sales

17-10-2013

Actelion has announced its financial results for the first nine months of 2013 revealing product sales…

ActelionBiotechnologyCardio-vascularCeptaris TherapeuticsEuropeFinancialTracleerVeletriVentavisZavesca

Actelion drops setipiprant, gets miglustat approval in Japan

04-04-2012

Switzerland-based Actelion Ltd (SIX: ATLN) announced says that it will re-direct its development efforts…

ActelionAsia-PacificBiotechnologyBrazavesInflammatory diseasesMiglustatRare diseasesRegulationResearchsetipiprantZavesca

Actelion buys option to acquire privately-held Trophos; posts strong 2nd-qtr 2010 results

20-07-2010

Switzerland-based Actelion, Europe’s largest biotechnology firm, has entered into a binding agreement…

ActelionBiotechnologyFinancialMergers & AcquisitionsPharmaceuticalTracleerTrophosZavesca

Soaring Tracleer sales boost Actelion’s 2009 financial results

19-02-2010

Switzerland-based Actelion, Europe’s largest biotechnology company, pleased investors yesterday…

BiotechnologybosentanDrug DiscoveryFinancialGlaxoSmithKlineGSKIloprostMiglustatPharmaceuticalTracleerVentavisZavesca

2008 profit doubles for Actelion on 2007 costs

02-03-2009

Swiss drugmaker Actelion's profit for full-year 2008 more than doubled in comparison to its 2007 result,…

bosentanIloprostMiglustatTracleerVentavisZavesca

1 to 9 of 42 results

Back to top